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Abstract
Dengue virus (DENV), which consists of four serotypes (DENV1-4),
infects over 400 million people annually. Previous studies have
indicated most human monoclonal antibodies (HMAbs) from
dengue patients are cross-reactive and poorly neutralizing. Rare
neutralizing HMAbs are usually serotype-specific and bind to
quaternary structure-dependent epitopes. We determined the
structure of DENV1 complexed with Fab fragments of a highly
potent HMAb 1F4 to 6 A resolution by cryo-EM. Although HMAb
1F4 appeared to bind to virus and not E proteins in ELISAs in the
previous study, our structure showed that the epitope is located
within an envelope (E) protein monomer, and not across neighbor-
ing E proteins. The Fab molecules bind to domain I (DI), and DI-DII
hinge of the E protein. We also showed that HMAb 1F4 can
neutralize DENV at different stages of viral entry in a cell type
and receptor dependent manner. The structure reveals the
mechanism by which this potent and specific antibody blocks viral
infection.
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Introduction
Dengue virus (DENV), a member of the family Flaviviridae, is trans-
mitted to humans by Aedes mosquitoes. Other flaviviruses that are
important human pathogens include West Nile virus (WNV), yellow
fever virus, Japanese encephalitis virus, and tick-borne encephalitis
virus. DENV targets susceptible populations residing in tropical and
sub-tropical regions of the globe. An estimated 400 million people
worldwide are infected with DENV annually, leading to approxi-
mately 100 million cases of dengue and 21 000 deaths (Thomas &
Endy, 2011; Bhatt et al, 2013).
DENV consists of four distinct serotypes (DENV1–4), and the
amino acid sequence variation of the polyprotein between serotypes
is about 25–40% (Holmes & Twiddy, 2003; Vasilakis & Weaver,
2008). People infected with DENV can be asymptomatic or develop
symptoms that range from a mild fever to severe dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS). A dengue-na€ıve indi-
vidual exposed to a primary infection develops long-lasting protective
immunity only to the infecting serotype (Imrie et al, 2007). A second
infection with a new serotype increases the risk of developing DHF/
DSS. The presence of cross-reactive but weakly neutralizing antibod-
ies (Abs) induced following the primary infection have been hypothe-
sized to be a cause of DHF or DSS through a mechanism known as
Ab-dependent enhancement (Halstead, 2003). Experts in the field
reason that a safe and effective vaccine against DENV will likely need
to be tetravalent (Raviprakash et al, 2008), since the induction of Abs
that neutralize a single serotype by monovalent vaccines may predis-
pose individuals to Ab-enhanced disease.
DENV is an enveloped virus, in which the nucleocapsid core is sur-
rounded by a lipid bilayer membrane. On the lipid envelope, there are
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180 copies each of membrane (M) and envelope (E) proteins (Kuhn
et al, 2002; Zhang et al, 2013a). These M and E proteins are arranged
with icosahedral symmetry with each asymmetric unit consisting of
three pairs of M and E proteins. The three individual E proteins in an
asymmetric unit each have a different local chemical environment.
The 180 copies of E protein are arranged into 90 head-to-tail homodi-
mers. Three of these homodimers lie parallel to each other forming a
raft. Together, the 30 E protein rafts on the DENV surface form a
herringbone pattern (Kuhn et al, 2002; Zhang et al, 2013a).
Crystal structures of the ectodomain part of the E protein showed
that it consists of three distinct domains, designated DI, DII and DIII.
E protein also likely exists as a head-to-tail oriented homodimer in
solution (Modis et al, 2003, 2005; Zhang et al, 2004). This molecule
is critical for viral entry into cells, as it mediates binding to cellular
receptors and also fusion between the virus and endosomal mem-
branes. In addition, E protein is the major target for neutralizing
Abs (Roehrig, 2003).
Studies with mouse monoclonal Abs (MAbs) showed that the
most potent neutralizing Abs are serotype-specific and bind to DIII
(Gromowski & Barrett, 2007; Sukupolvi-Petty et al, 2007; Shrestha
et al, 2010). In contrast, a large fraction of potent neutralizing
anti-DENV Abs produced in humans does not appear to bind to DIII
(Wahala et al, 2009, 2012; Costin et al, 2013). These human MAbs
(HMAbs) bind only to whole virus particles but not to recombinant
E (rE) protein, suggesting that they recognize quaternary structure-
dependent epitopes (Beltramello et al, 2010; De Alwis et al, 2012;
Teoh et al, 2012). One such HMAb is 1F4, a DENV1-specific Abs
(De Alwis et al, 2012). Here, we have solved the cryo-electron
microscopy (cryo-EM) structure of Fab 1F4 complexed with DENV1
to 6 A resolution. Surprisingly, unlike other HMAbs recognizing
quaternary structure-dependent epitopes (Kaufmann et al, 2010;
Teoh et al, 2012), 1F4 does not bind across neighboring E proteins.
Results
HMAb 1F4 exhibits potent neutralizing activity in vitro and in
vivo, and it inhibits virus infection at different stages of viral
entry depending on the cell type and receptor
A neutralization assay conducted with HMAb 1F4 and DENV1 in
human monocytic U937 cells expressing dendritic cell-specific inter-
cellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) dem-
onstrated that it is a highly potent Ab with a Neut50 value of
0.03 lg/ml (Fig 1A). In addition, the Fab fragment of HMAb 1F4
also neutralized the virus, although the potency of the Fab was
reduced by approximately 4-fold (Neut50 value of 0.11 lg/ml) com-
pared with full-length IgG (Fig 1B).
In mice that had been given 20 lg of HMAb 1F4 prior to infection
with a sub-lethal dose of DENV1, a significant reduction in the viral
genomic RNA copy number as compared to the isotype control was
observed in serum and bone marrow (Fig 2A and B).
To test whether HMAb 1F4 inhibits receptor binding in Vero and
DC-SIGN-expressing U937 cells, we compared the neutralization
profile of HMAb 1F4 to DENV before and after the virus was
allowed to attach to cells. In Vero cells, HMAb 1F4 was just as effec-
tive in neutralizing virus when the Ab was added to virus prior to
exposure to cells (FRNT50 of 0.41 lg/ml) as when added after
attachment to cells (FRNT50 of 0.37 lg/ml) (Fig 1C). This suggests
that HMAb 1F4 neutralizes virus infection in Vero cells by inhibiting
a step after virus attachment to cells. In experiments where the virus
was exposed to HMAb 1F4 after attachment to cells, DC-SIGN-
expressing U937 cells showed a similar neutralization profile as
Vero cells (Neut50 of 0.40 lg/ml) (Fig 1D). However, when virus
was exposed to Ab before attachment to DC-SIGN-expressing cells,
the neutralizing concentration was approximately 6 fold lower
(Neut50 of 0.07 lg/ml) (Fig 1D). These data suggest that the Ab can
prevent virus from attaching to DC-SIGN-expressing cells in addition
to neutralizing the virus after attachment to the cells.
Cryo-EM structure of DENV-1 complexed with Fab 1F4
For the cryoEM reconstruction of the Fab 1F4-DENV1 complex, the
DENV1 primary isolate strain PVP159 was used, and neutralization
tests showed that the Ab neutralized this virus strain with high
potency (supplementary Fig 1). A micrograph of an untreated
control DENV1 (PVP159) (supplementary Fig 2), which was grown
at 28°C in C6/36 cells and kept at 4°C, showed that the sample con-
sisted of mainly smooth mature virus particles, with about 15%
spiky immature particles and a few broken particles. DENV2 parti-
cles have been shown to exhibit a change from a smooth to a
bumpy surface when incubated at 37°C for 30 min (Fibriansah et al,
2013; Zhang et al, 2013b). Incubation of DENV1 (PVP159) at 37°C
for 30 min, on the other hand, did not show any increase in the
number of bumpy particles compared to the sample that was never
exposed to 37°C (supplementary Fig 2). This indicated that the
DENV1 strain PVP159 did not undergo similar structural changes
when incubated at 37°C for 30 min as had been observed in DENV2.
However, we cannot eliminate the possibility of small local domain
movements of the E proteins on DENV1 surface.
The expansion of the virus structure as observed in DENV2, does
not seem to enhance infectivity in mammalian cells. Fibriansah et al
(2013) showed that DENV2 titres were similar at both 37 and 28°C.
This implied that both structural forms are equally infectious to
mammalian cells. This indicates there may not be a strong selection
pressure for the virus to adopt the expanded structure.
Cryo-EM reconstruction of Fab 1F4 complexed with DENV1
strain PVP159 when incubated at 4 or 37°C resulted in similar maps.
Hence, further structural analysis was done using the complex
formed at 4°C as the viral components and Fab 1F4 were likely to
be less mobile, thus allowing us to achieve higher resolution. The E
protein shell of the cryo-EM map of the Fab-virus complex was
solved to 6 A resolution (Fig 3A–D). At this resolution, we were
able to observe densities of the helical ridges (Fig 3C, left) of the E
protein transmembrane region. On the other hand, the densities cor-
responding to the Fab molecules are poorer in resolution (Fig 3D).
Resolutions of the Fab variable and constant regions were about 7.7
and 12 A, respectively. The difference in resolution between the Fab
variable and constant regions suggests high flexibility of the elbow
angle between these domains (Fig 3B and D).
Fitting of E protein and Fab molecules into the cryo-EM density
map showed that the Fab molecules bind in an identical way to two
of the three individual E proteins (molecules A and B) in an asym-
metric unit (Fig 4A and B). Since the resolution of the map did not
permit observation of side chain densities, interacting residues
between Fab and E protein were identified by observing pairs of Ca
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atoms of less than approximately 8 A in distance. The possibility of
hydrogen bonding and hydrophobic interactions between the side
chains of these residues was also taken into consideration. The foot-
print of the Fab 1F4 molecule on an E protein is approximately
1340 A2, which is bigger than that of a typical Ab footprint on anti-
gen (900–1000 A2) (Davies et al, 1990; Lok et al, 2008; Austin et al,
2012), but smaller than that of MAb E16 on WNV E protein
(1550 A2) (Nybakken et al, 2005). One Fab 1F4 molecule binds to
an E protein monomer and not across E proteins. The majority of
the footprint of Fab 1F4 is on E protein DI, with some interactions
with the DI-DII hinge region (Fig 4B). The epitope, consisting of 26
amino acids, is located on the Do strand and the downstream Doa
loop (46–52), Eo strand (136–138), part of the EoFo loop, Fo strand
(155–165), Go strand, the following GoHo loop (170–177), and kl
loop (272–276) (Fig 4C). Comparison of the epitope residues
between DENV serotypes (Fig 4C) revealed significant variation,
which likely explains the serotype specificity of HMAb 1F4. A total
of 27 interacting residues are located on the complementarity deter-
mining regions (CDRs) of the Fab molecule: 14 residues from the
light chain and 13 residues from the heavy chain (Fig 5A and B).
Also, two other non-CDR related interactions were observed. The
side of the Fab molecule interacted with the N153 glycosylation site
on the same E protein molecule (Fig 6, left) and also the N67 glyco-
sylation site of a neighboring dimer-related E protein (Fig 6, right).
Fab 1F4 is unable to bind to the E proteins near the 3-fold verti-
ces (molecule C) (Fig 4A). Superposition of the three individual E
protein molecules did not show significant structural differences,
suggesting that the lack of binding of Fab to molecule C may be due
to steric hindrance caused by the neighboring E proteins (Fig 7A).
Comparison of the accessibility of the epitopes on the three E pro-
teins in an asymmetric unit showed that the epitopes on molecules
A and B are completely exposed (Fig 7B and C), while the epitope
on C molecule (near to 3-fold vertices) is partially covered by DIII of
a neighboring E protein (Fig 7D).
Discussion
HMAb 1F4 is a strongly neutralizing Ab against DENV1, as shown
in vitro (Fig 1) and in the AG129 mouse model (Fig 2). As observed
A B
C D
Figure 1. The mechanism of HMAb 1F4 neutralization of DENV1 (Western Pacific 74 strain) in Vero or DC-SIGN expressing U937 cell lines.
A, B Both HMAb 1F4 IgG (A) and its Fab fragment (B) neutralized DENV1 infection in U937 cells expressing DC-SIGN although the Fab fragment required a 4-fold higher
concentration.
C HMAb 1F4 inhibited a post-attachment step of virus infection in Vero cells. HMAb 1F4 had similar neutralization activities when exposed to virus pre-
(FRNT50 = 0.41 lg/ml) or post-attachment (FRNT50 = 0.37 lg/ml) to Vero cells. The two experiments were done with two replicates. Error bars represent standard
deviations. Pre and post-attachment neutralization curves are not significantly different by a 2-way repeated measures analysis of variance (RM ANOVA).
D HMAb 1F4 prevented virus infection of DC-SIGN-expressing U937 cells by blocking both virus attachment and also a post-attachment step. Error bar represented
standard deviations. Neutralization curves of pre and post-attachment groups are significantly different by 2-way RM ANOVA, with a P < 0.001.
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previously (Beltramello et al, 2010; De Alwis et al, 2012), potent
HMAbs usually bind to quaternary structure-dependent epitopes, as
determined by the ability of the Ab to bind to whole virus particles
and not rE protein in ELISAs. HMAb 1F4 is unique compared to the
previously published HMAbs (Kaufmann et al, 2010; Teoh et al,
2012) that bind to quaternary structure-dependent epitopes, as HMAb
1F4 does not bind across the interface between separate E proteins.
Instead, it recognizes E protein monomers that adopt a conformation
that only exists when the protein is displayed on virus particles.
The cryo-EM structure of another strongly neutralizing DENV1-
specific HMAb, 14c10, in complex with DENV1 had been solved pre-
viously (Teoh et al, 2012). Comparison of the HMAb 1F4 and 14c10
epitopes showed that HMAb 1F4 binds to an E protein monomer
whereas 14c10 binds across two E proteins (Fig 8). Both HMAbs
1F4 and 14c10 bind mainly to DI and the hinge between DI and DII.
In addition, HMAb 14c10 also binds to the DIII of a neighboring E
protein. There is another report of the crystal structure of a chim-
panzee Fab 5H2 complexed with DENV4 E protein (Cockburn et al,
2012). The MAb 5H2 is a DENV4 specific antibody that binds to DI
(Lai et al, 2007). The complex structure showed that the MAb 5H2
epitope is located on b-strands Fo, Go,Ho and the loops between
them as well as the loop downstream of b-strand Io (DI-DIII linker).
Figure 2. Prophylactic efficacy of HMAb 1F4 in DENV1-inoculated AG129
mice.
A, B Mice were administered 20 lg of HMAb 1F4 or 50 lg IgG1 isotype
control 24 h prior to a sub-lethal dose of 5 × 106 pfu of DENV1 Western
Pacific 74. Serum viremia (A) and bone marrow viral load (B) were
determined 3 days post-infection by qRT-PCR. One representative
experiment of two is shown, with n = 4 mice per group. DENV1 limit of
detection is indicated by the dashed line. *P = 0.0209 compared to IgG1




Figure 3. The cryo-EM structure of Fab 1F4 complexed with DENV1.
A Cryo-EM map of Fab 1F4 complexed with DENV1 showed 120 copies of Fab (blue) bound to the virus surface (cyan). White triangle indicates an icosahedral
asymmetric unit and the numbers represents the vertices.
B Cross-section of a quarter of a cryo-EM map.
C The resolution of the cryoEM map is 6 A. Regions of the density map corresponding to trans-membrane a-helices (left) and b-strands (right).
D The density map corresponding to Fab 1F4. The density of the constant region (indicated by arrow) is much poorer than the variable region indicating the constant
region is flexible.
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Similar interactions between Fab and amino residues on b-strands
Fo and Go and the loop FoGo were also found in the complex struc-
ture of Fab 14c10 (Teoh et al, 2012) and 1F4 (Fig 4 and 8), but
interactions with DI-II hinge region was not observed in the Fab
5H2 complex structure. Since the Fab 5H2 complex structure is a
crystal structure, its ability to bind across E proteins and also the
level of occupancy on the DENV particle surface are unknown.
However, analysis of the epitopes on all three E protein molecules
in an asymmetric unit suggests that the epitope would be occluded
in the E protein near the three-fold vertices (molecule C) (Fig 8).
The observation that the epitopes bound by HMAbs 14c10 and 1F4
overlap at the DI-DII hinge and it is not recognized by chimpanzee
MAb 5H2 suggests that this region could be important in eliciting
type-specific neutralizing antibody responses in humans.
Although Fab 1F4 binds to E protein monomers on the virus, it




Figure 4. The epitope bound by Fab 1F4.
A Densities of Fab 1F4 on E proteins in two icosahedral asymmetric units. Fab 1F4 molecules bind to molecules A and B in each asymmetric unit.
B Open-book representation of Fab 1F4 binding to E protein. The E protein DI, DII and DIII are colored in red, yellow and blue (top), respectively, whereas the Fab 1F4
heavy and light chains are colored in green and cyan (bottom), respectively. The epitope bound by Fab 1F4 is located on the DI and DI-II hinge regions (top). The
epitope on E protein bound by the heavy and light chain are colored in green and cyan, respectively (top). Also the epitope on DI that interacted with both heavy
and light chains are colored in purple (top). The paratope on heavy and light chain (bottom) are colored in its corresponding interacting residues on the DI (red) and
DII (yellow) E protein, paratope binding to both DI and II on the E protein is colored in pink.
C Ribbon representation of the HMAb 1F4 epitope on E protein (top) and also sequence alignment of the epitope region between all dengue virus serotypes (bottom).
The b-strand and loop of the epitope are colored in orange and black, respectively (top). In the bottom panel, the secondary structures are shown above the amino
acid sequence. The amino acid residues that interact with Fab 1F4 are highlighted in the same coloring scheme as in (B). The amino acid sequences are derived
from DENV1 strain PVP159, DENV2 strain S16803, DENV3 strain Thailand 1995 and DENV4 strain Dominica 1981.
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protein (De Alwis et al, 2012). This indicates that Ab binding may
requires a certain E protein conformation that is only present when
the E protein is assembled on the virus. Part of the Fab 1F4 epitope
is located on the kl loop (273–276) in the DI-II hinge (Fig 9A). Nota-
bly, residue 274 in the kl loop was reported to be important for
HMAb 1F4 binding, since one escape mutant virus containing a
substitution at this position (G274E) completely abolished Ab binding
(De Alwis et al, 2012). When DI of the crystal structures of the
DENV2 and DENV3 rE proteins were superimposed onto DI of the E
proteins from the cryo-EM structures of whole virus, the conforma-
tion and orientation of the kl loop of the rE proteins were observed
to be more variable than that of the virus E proteins (Fig 9A and B).
A
B
Figure 5. Interaction interface between Fab 1F4 and DENV1 E protein.
A Open-book representation showing the electrostatic potential of the interaction interface on the E protein (left) and the Fab 1F4 (right). The blue and red colors
indicate positive and negative charges, respectively, whereas the white color shows neutral charge. The dotted lines indicate the border of the footprint between
heavy and light chains on the E protein epitope (left) and also the corresponding border on the antibody paratope (right). Residues on E protein identified in the
neutralization escape mutants (K47 and G274) are indicated, together with other residues that have opposite charges in other serotypes. The corresponding
interacting residues on the Fab 1F4 light and heavy chains are indicated with cyan and green colored fonts, respectively.
B Table of the list of putative interactions between DENV1 and Fab 1F4.
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Figure 6. Fab 1F4 also has non-CDR related interactions with glycan chains on N153 on the same E protein and the N67 of a neighboring E protein. Left and
right panels show different views of these interactions.The heavy and light chains of Fab 1F4 are colored in green and cyan, respectively, whereas the E protein molecules A




Figure 7. Analysis of the accessibility of the epitope on all three individual E protein molecules in an asymmetric unit.
A Superposition of the three individual E protein molecules in an asymmetric unit (molecules A–C). The epitope location is indicated by a rectangular box. Molecules
A, B and C in each asymmetric unit are colored in yellow, red and gray, respectively. The E proteins have similar conformation indicating that the lack of Fab
binding to molecule C is mainly due to the blockage of the epitope by a neighboring E protein molecule.
B–D Molecules A, B, and C in each asymmetric unit are colored in yellow, red and gray, respectively. The epitope is colored in the same coloring scheme as in Fig 4B. The
epitopes on molecules A (B) and B (C) (circled) are fully accessible. (D) In contrast, the part of the epitope on molecule C is blocked by DIII of a neighboring E protein
(indicated by arrow). For clarity, one of the E proteins (left) is represented as a transparent surface to show the hidden part of an adjacent epitope (marked by*).
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The hinge angle of the E protein on the virus particle is likely to be
stabilized by the interactions between E to E ectodomains and also
E ectodomains with the membrane-associated E and M stem regions
(Kostyuchenko et al, 2013) (supplementary Fig 3).
Surface electrostatic potential analysis of the interaction interface
showed that the majority of interactions between Fab 1F4 and E pro-
tein on DENV are likely to be between polar residues forming hydro-
gen bonds or salt bridges (Fig 5A and B). The 1F4 paratope on the
light (L) chain consists of a mixture of negatively charged and hydo-
phobic residues, while those on the heavy (H) chain are largely
positively charged. As expected, the H-chain contacts with the
negatively charged residues of the epitope on E protein, while
L-chain engages with positively charged and hydrophobic residues.
There have been two HMAb 1F4 neutralization escape mutant
viruses isolated to date - one of the escape mutant viruses contained
a K47E amino acid substitution and the other G274E (De Alwis et al,
2012). These results are consistent with the epitope identified by
our cryo-EM structure. These mutations result in a change in the
surface charges, likely causing the Ab to be repelled from the virus
surface (Fig 5A).
Sequence comparison of the epitope residues of E proteins
between DENV1-4 showed that some of the corresponding residues
on DENV2-4 have opposite charges (Fig 4). For instance, in DENV1,
positions 157 (Glu) and 160 (Thr) are occupied by negatively charged
residues, that can interact with positive patches on the H-chain para-
tope (Fig 5A and B), while positively charged lysine residues are
present in the same positions in DENV2. In DENV1, the lysine residue
in position 136 interacts with a negatively charged patch on the bor-
der of the H- and L-chain (Fig 5A and B), while in DENV2 and
DENV4, the same position contains a glutamate residue (Fig 4). Fur-
thermore, position 274 in DENV4 consists of an aspartic acid residue.
This is similar to the amino acid substitution in one of the isolated
neutralization-escape mutants (G274E). A comparison between the
residues in the epitope of DENV1 and DENV3 showed that there are
also changes in hydrophobicity at positions L46Q, T160V, T171V,
Q174I and T176P. These differences in the epitope may explain the
molecular basis for the serotype specificity of the Ab.
DENV and other flaviviruses enter their host cell via receptor-
mediated endocytosis (Lindenbach & Rice, 2003; Chu & Ng, 2004;
Hidari & Suzuki, 2011). After the virus attaches to the receptor and
Figure 8. Comparison of epitopes bound by HMAb 1F4 (left), HMAb14c10 (middle) and 5H2 (right). The epitopes are colored in green.
A
B
Figure 9. Comparison of the DI-DII hinge angle of the crystal structures
of rE protein with the cryo-EM structures of virus E protein.
A Superposition of the crystal structures of rE and the subnanometer
resolution cryo-EM structures of virus E proteins showed that the hinge
angles of rE proteins are variable whereas those on the virus surface are
largely conserved. DI of these structures was superimposed using ‘LSQ
superpose’ in COOT (Emsley et al, 2010).
B Zoom-in view of the part of the HMAb 1F4 epitope that consists of the kl
loop (represented as sticks) in the DI-II hinge region. The kl loops from the
viruses (left) showed conserved conformation whereas those from the rE
proteins (right) showed varying conformations. Residue 274, which is
critical for HMAb 1F4 binding (De Alwis et al, 2012), is shown as a sphere.
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the complex is endocytosed, the low pH environment of the endo-
some causes the E proteins to rearrange from homodimers to homo-
trimers and in the process, expose its fusion loops. The fusion loop
interacts with the endosomal membrane, which subsequently
results in the fusion of the viral membrane with the endosomal
membrane, thereby releasing the viral genetic material (Bressanelli
et al, 2004; Modis et al, 2004). Abs can interfere with the several
different steps of the infection, e.g. attachment to the receptors or
ancillary receptors or E protein arrangement during fusion at low
pH. By using pre- and post-attachment neutralization assays, we
showed that HMAb 1F4 inhibited a post-attachment step of virus
infection in Vero cells, whereas in DC-SIGN-expressing U937 cells,
the Ab was also able to block virus attachment.
The previous structural study of carbohydrate recognition
domains (CRD) of DC-SIGN complexed with DENV, showed that one
CRD binds across two glycosylation sites at position 67 from two
neighboring E proteins (molecules A and B, Fig 10) (Pokidysheva
et al, 2006). Superposition of the cryo-EM Fab 1F4-DENV1 and the
CRD-DENV complex structures suggests that HMAb 1F4 prevents
attachment of the virus to DC-SIGN receptors on dendritic cells. This
blocking action of the Fab is predicted to occur because when Fab
1F4 binds to virus, it will interact with the glycan at N67 on the
neighboring dimer-related E protein (Fig. 6), making it unavailable
for binding to the CRD. In addition, superposition of the two com-
plexes showed a clash between Fab 1F4 and the CRD of DC-SIGN,
suggesting that simultaneous binding of both molecules is not possi-
ble. This is consistent with the pre- and post-attachment neutraliza-
tion tests using DC-SIGN-expressing U937 cells showing that HMAb
1F4 was able to prevent virus attachment to cells (Fig 1D).
The pre- and post-attachment assays using Vero or DC-SIGN-
expressing U937 cells also showed that HMAb 1F4 was able to block
virus infection at a post-attachment step. Flexing of the DI-DII hinge
region is thought to be important for exposing the fusion loop of the
virus E protein at low pH so as to facilitate the fusion of virus to the
endosomal membrane (Bressanelli et al, 2004; Modis et al, 2004).
HMAb 1F4, which binds to this region, may prevent the structural
changes required for fusion. Superposition of the DI of E proteins of
the HMAb 1F4-E complex structure with the crystal structure of the
E protein post-fusion structure [PDB ID 3G7T, (Nayak et al, 2009)]
showed that their hinge kl loop had a different conformation
(Fig 10B(i)). This suggests that Ab binding to E protein on virus
may lock the kl loop, preventing it from undergoing the structural
changes required for fusion. Furthermore, superposition of the Fab
1F4-E protein complex and the post-fusion trimeric E protein crystal
structure showed significant clashes of the Fab molecule with the
neighboring E monomers in the post-fusion structure (Fig 10B(ii)).
This indicates that when Fab 1F4 is bound to the virus, the E protein
is not able to arrange into the post-fusion trimeric structure.
In summary, HMAb 1F4 binds to the DI and DI-II hinge regions
of the E protein monomer and that Ab binding is likely to be sensi-
tive to the hinge angle between DI-II. The overlap between the epi-
topes of 1F4 and another anti-DENV1 Ab 14c10, suggests that the
DI-DII hinge region of the E protein is likely to be one of the princi-
pal epitopes in E protein that elicits a type-specific neutralizing Ab
response. This work also suggests that the induction of neutralizing
antibodies by vaccines incorporating soluble E protein monomers or
dimers may be improved if the hinge angle of the E protein is identi-
cal to that on virus surface.
Materials and Methods
Virus sample preparation
DENV1 strains Western Pacific 74 and PVP159 were used in the
present study. DENV1 strain PVP159 (DEN1/SG/07K3640DK1/
2008) was obtained from the EDEN patient cohort (Low et al,
2006). DENV1 strains Western Pacific 74 and PVP159 were used in
neutralization assays, whereas strain PVP159 was used in ELISA
and the cryo-EM structure determination. DENV-1 strain PVP159
contains 14 amino acid residues changes (positions 7, 17–19, 88,
155, 161, 171, 203, 324, 339, 380, 436, and 461) in the E protein
when compared to the Western Pacific 74 strain. Three of these
amino acid residues are located in the epitope of HMAb 1F4, previ-
ously identified by neutralization escape mutants (De Alwis et al,
2012), but the amino acids are similar in properties. Specifically,
PVP159 contains residues S155, T161 and T171 while the Western
Pacific 74 strain contains T155, I161 and S171. Only the amino
acid residue in position 161 was not replaced with a similar amino
acid. However, this residue is unlikely to be important for HMAb
1F4 binding, as the Ab is able to neutralize both DENV1 strains.
All viruses were grown in C6/36 Aedes albopictus mosquito cells
at 28°C and purified as described previously (Kuhn et al, 2002).
The purified virus was concentrated and buffer exchanged into
NTE buffer (12 mM Tris–HCl pH 8.0, 120 mM NaCl and 1 mM
EDTA) using an Amicon Ultra-4 centrifugal concentrator (Millipore,
Billerica, MA, USA) with a 100-kDa molecular-mass cut-off filter.
The purity of the virus preparation was assessed by Coomasie
blue-stained SDS-PAGE. In addition to the E protein, capsid and M
protein bands, it also showed a faint band at 25 kDa, which corre-
sponded to pre-membrane (prM) protein. This indicated that there
was only a slight contamination with immature virus particles. The
E protein concentration was estimated by comparing the E protein
band with a bovine serum albumin protein standard of known
concentration.
DENV1 neutralization assays
The anti-DENV neutralizing properties of full-length IgG or Fab frag-
ment of HMAb 1F4 were assessed using a flow cytometry-based
neutralization assay with U937 cells stably transfected with DC-
SIGN as previously described (Kraus et al, 2007). Briefly, IgG or Fab
1F4 were serially diluted three-fold from 39 to 0.002 nM, and incu-
bated for 1 h at 37°C with DENV1 (Western Pacific 74). The Ab-
virus mix was then added to U937 cells expressing DC-SIGN and
incubated at 37°C for 2 h, after which cells were washed twice with
fresh infection medium and placed back at 37°C. Approximately
24 h post-infection, the cells were fixed, stained and the percentage
of infected cells was assessed by flow-cytometry.
Pre- and post-attachment neutralization assays
Pre-attachment: Vero cells in 24-well plates and reagents were
cooled to 4°C. Virus and diluted Ab were incubated at 4°C for 1 h,
then transferred to chilled Vero cells and incubated for another 1 h
at 4°C. After incubation, cell monolayers were washed 3× with cold
PBS, and cells were incubated at 37°C for 4 days before fixing and
staining for foci. Pre-attachment assays with DC-SIGN expressing
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U937 cells were conducted similarly, with each experimental well
containing 5 × 104 pre-chilled cells.
Post-attachment: Vero cells in 24-well plates and reagents
were chilled at 4°C. Virus was added to cells and allowed to
bind for 1 h at 4°C. Unbound virus was washed off by washing
twice with cold PBS. Ab was then added to virus-bound cells
and incubated for 1 h at 4°C. Following incubation, cell monolayers
were washed once with cold PBS and placed at 37°C for 4 days
before fixing and staining for virus foci. Post-attachment neutral-
ization assays with DC-SIGN expressing U937 cells were conducted
similarly to the assay described above for Vero cells. After 24 h
of infection, DC-SIGN expressing U937 cells were fixed and




Figure 10. Possible neutralization mechanisms by HMAb 1F4.
A HMAb 1F4 may block DC-SIGN from binding to the glycosylation site on N67. One DC-SIGN molecule binds across two N67 glycans on the virus surface. When Fab
1F4 is allowed to bind to the virus surface, it engages the N67 glycan on molecule B. This would cause steric hindrance thereby preventing the virus from binding to
DC-SIGN on the surface of dendritic cells (Pokidysheva et al, 2006). Superposition of the cryo-EM complex structures of DENV1-Fab 1F4 and the DENV2-
carbohydrate recognition domain (CRD) of DC-SIGN (PDB code 2B6B) showed that the Fab and the CRD molecules clashed. This indicates that simultaneous binding
of these molecules on the virus surface is not possible. E protein molecules A, B and C are colored in light gray and molecules A, B and C in gray. DC-SIGN is shown
as a transparent orange surface. The glycosylation sites on N67 and N153 are marked as red stars and blue squares, respectively. The clashes between the Fab and
DC-SIGN molecules are indicated by arrows.
B Fab 1F4 may interfere with the E protein dimer to trimer structural changes during fusion of the virus to the endosomal membrane. (i) The DI-DII hinge of the
whole virus E protein has a different angle compared to the crystal structure of the trimeric post- fusion rE protein. This suggests that the binding of HMAb 1F4 to
virus may lock the E protein hinge thus preventing the kl loop from undergoing structural changes to the post-fusion structure. The E protein on the virus and the
post-fusion trimeric state are colored in blue and pink, respectively. (ii) Superposition of the cryo-EM Fab 1F4-DENV1 E protein structure onto the post-fusion
trimeric E protein crystal structure. The Fab 1F4 molecule clashed with DIII of a neighboring E protein in the post-fusion trimeric structure (indicated by arrow).
Two molecules of E protein are shown as surfaces (colored in light gray and dark gray) and one molecule is shown as ribbons. Fab 1F4 is drawn as a transparent
surface.
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AG129 mouse infections
The animal study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Animal Care and Use Committee at the University
of California, Berkeley (R252-1013B). AG129 mice (van den Broek
et al, 1995) were bred at UC Berkeley. Mice 6–8 weeks of age were
administered 20 lg of hMAb 1F4 or 50 lg of an isotype control
(IgG1) intraperitoneally (i.p.) in a total volume of 200 ll, 24 h prior
to DENV infection. A sublethal dose of DENV1 Western Pacific 74
(5 × 106 pfu) was administered intravenously (i.v.) in a total vol-
ume of 100 ll. Three days post-infection, mice were sacrificed.
Serum was obtained from whole blood by centrifugation and stored
at 80°C. Bone marrow cells were processed as previously
described (Balsitis et al, 2010) by perfusing femurs with 1 ml of
cold, complete RPMI containing 5% FBS, 10 mM Hepes, and 100 U
penicillin/100 lg streptomycin. Processed bone marrow cells were
stored short-term in RNALater (Ambion, Austin, TX, USA) at 4°C
prior to RNA extraction.
RNA extraction and quantitative RT-PCR
RNA was extracted from 20 ll of serum using the QIAamp Viral RNA
mini kit (Qiagen, Valencia, CA, USA), as per the manufacturer’s
instructions. Similarly, RNA was extracted from the 1 ml bone mar-
row collection using an RNeasy Mini kit (Qiagen). The ABI Prism
Sequence Detection System 7300 was used to perform quantitative
RT-PCR (qRT-PCR). Viral load was determined using previously pub-
lished primers and probe sequences (Johnson et al, 2005) and the
Verso 1-Step qRT-PCR kit as follows: 2 ll RNA sample, 1X 1-step
QPCR Mix, 1 lM forward and reverse DENV1 primers, 0.1 lM
DENV1 probe, and Verso enzyme mix (final 1X reaction volume).
The cycling parameters were as follows: 1 cycle of reverse transcrip-
tion (30 min at 50°C), 1 cycle of Thermo-Start activation (12.5 min
at 95°C), and 40 cycles of denaturation (15 s at 95°C) and annealing/
extension (1 min at 60°C). Serum viral load was determined accord-
ing to the following equation: GE/ml = (mean quantity/2 ll) (RNA
extraction eluation volume/volume of serum per RNA extraction)
(1000 ll/1 ml). Each DENV1 plate was run using a 10-point stan-
dard curve. To normalize for variance between tissues, bone marrow
samples were analyzed for levels of GAPDH (Applied Biosystems,
Taqman rodent GAPDH control kit) with manufacturer-supplied
primers and probe (139 nM and 200 nM final concentration, respec-
tively) in conjunction with the Verso 1-Step qRT-PCR kit. The GAP-
DH 8-point standard curve was run using control RNA provided in
the Taqman rodent GAPDH control kit. GAPDH lg/ml was calculated
as follows: (mean GAPDH quantity/2 ll) (dilution factor) (1000 ll/
1 ml). Final GE/lg was then determined by (GE/ml) divided by
(GAPDH lg/ml). The limit of detection (LOD) for the serum was
based on the lowest DENV1 standard detection limit, while the bone
marrow LOD (GE/lg GAPDH) was determined by dividing the DENV1
LOD by the average GAPDH levels from all bone marrow samples.
Cryo-EM image collection and processing
DENV1 was mixed with Fab 1F4 in a molar ratio of one Fab mole-
cule to every E protein and then incubated at one of two different
temperatures (4 or 37°C), for 30 min followed by another 2 h at
4°C. The corresponding controls (DENV1 without Ab at 4 or
37°C) were also included. A 2.5 ll sample was pipetted onto
ultra-thin carbon-coated lacey carbon grids (Ted Pella), and then
blotted with filter paper for 2 s and flash-frozen in liquid ethane
using the FEI Vitrobot Mark IV plunger. The frozen grid was kept
at liquid nitrogen temperature. The virus particles were imaged
using a 300-kV FEI Titan Krios electron microscope at a nominal
magnification of 47 000 with an electron dose of 17.5 e/A2.
The images were captured on a direct electron detector (Falcon,
FEI), resulting in a pixel size of 1.81 A per pixel, at an under-
focus range of 1–4 lm. Images showing drift and strong astigma-
tism were discarded, and 752 images were selected for further
processing.
Cryo-EM image reconstruction
Reconstruction of the DENV1-Fab complex particles was initi-
ated by manually picking the spiky-looking unbroken particles
using the program e2boxer. A total of 10 270 particles were
selected and the contrast transfer function parameters were
determined by using e2ctf. Following the class averaging, an
initial model was generated based on a set of class-averages
using e2initialmodel. The programs e2boxer, e2ctf and e2initial-
model are available in EMAN2 software package (Tang et al,
2007). The initial model was used in the orientation search of
the particles that was carried out using Multi-Path Simulated
Annealing procedure (Liu et al, 2007). Following the orientation
search, a 3D reconstruction was done with make3d from EMAN
(Ludtke et al, 1999). The resolution of the final map was deter-
mined by plotting the Fourier shell correlation coefficient
between two half datasets-reconstructed maps with a cut-off
value of 0.5.
Model fitting
Interpretation of the map was done, by fitting the map using the
cryo-EM structure of the DENV2 (Protein Data Bank [PDB]
accession code 3J27). As for the Fab molecules, a homology
model was built for Fab 1F4 by using Swiss-model server
(Arnold et al, 2006). Two human Ab structures (Protein Data
Bank (PDB) codes 4ERS and 3G04) were used as templates for
the homology modeling of Fab 1F4 heavy and light chains,
respectively. After an initial manual fitting using the program
Chimera, the fit was further optimized using the “Fit in Map”
command in Chimera (Pettersen et al, 2004). The amino acid
sequences of the fitted DENV2 E and membrane proteins were
then mutated to DENV1 residues by using COOT (Emsley et al,
2010). Further optimization of the fit for the molecules was
done, by using the molecular dynamics flexible fitting (MDFF)
program (Trabuco et al, 2009) in VMD (Humphrey et al, 1996)
and NAMD (Phillips et al, 2005). Symmetry restraints were
applied to avoid clashes between neighboring molecules and a
factor of 0.5 was used to weigh the contribution of the cryo-EM
map in the overall potential energy of the molecular dynamic
simulation. The simulation involved 20 000 steps of minimiza-
tion followed by 100 000 steps of molecular dynamics before
converging into a stable solution. The final structure was
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observed to be free of misfits and clashes by using the O pro-
gram (Jones et al, 1991).
Structural analysis
The other structural and sequence analysis were carried out using
a series of computer programs: Gerstein’s accessible surface
calculator (Gerstein & Richards, 2012) in StrucTools server
(http://helixweb.nih.gov/structbio/basic.html) for calculating the
contact area between two molecules, Multalin (Corpet, 1988)
server for multiple sequence alignment, LSQ Superpose in COOT
for superimposition of protein structures, PROPKA (Li et al, 2005)
for assigning protonation states at a particular pH, and PDB2PQR
server (Dolinsky et al, 2004) to generate input files for evaluating
the electrostatic properties of biomolecular system in Adaptive
Poisson-Boltzmann Solver (Baker et al, 2001). Chimera was used
for visualization of the structures. The amino acid sequences used
for comparison were DENV2 strain S16803 (GenBank accession
code ADA00411.1), DENV3 strain Thailand 1995 (GenBank acces-
sion code AY676376) and DENV4 strain Dominic 1981 (GenBank
accession code AAK01233.1). The E protein structures used in the
structural comparison were two crystal structures of DENV2 E
proteins (PDB code 1TG8 and 1OAN), a crystal structure of
DENV3 E protein (PDB code 1UZG), and two cryo-EM recon-
structed structures of DENV1 and DENV2 (PDB codes 4AZX and
3J27, respectively).
Protein structure accession number
The cryo-EM map was deposited in the Electron Microscopy Data-
base under accession number EMD-2442. The modeled E protein –
Fab 1F4 complex structure was deposited in the Protein Data Bank
under accession code 4C2I.
Statistical analysis
Data in animal experiments were analyzed using the STATA12
software (StataCorp LP, College Station, TX, USA) and a two-tailed
Wilcoxon rank-sum test. Analysis of attachment assays were con-
ducted using a 2-way repeated measures analysis of variance (RM
ANOVA).
Supplementary information for this article is available online:
http://embomm.embopress.org/
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The paper explained
Problem
Dengue is a tropical disease that affects hundreds of millions of
people annually and poses an economic burden in many tropical
countries. There are four dengue serotypes (DENV1-4). Infection with
virus from one serotype in a primary infection may potentially prime
the individual to develop a more severe disease when infected with
virus from another DENV serotype in a secondary infection. This is
likely caused in part by antibody-dependent enhancement of infection
of virus into monocyte/macrophage cells via Fcc receptors, facilitated
by the binding of non-neutralizing antibodies to virus. This phenome-
non complicates the development of vaccines and therapeutics. One
strategy to produce a safe dengue antibody therapeutic is to identify
four potently neutralizing antibodies, each specific to a DENV sero-
type, and to then combine them into a cocktail. We therefore con-
ducted structural studies to understand how a potent human
antibody binds and neutralizes DENV1.
Results
Human monoclonal antibody (HMAb) 1F4 was shown to be highly
neutralizing in vitro and in an AG129 mouse model. We determined
the structure of DENV1 complexed with Fab 1F4 to a resolution of 6
A by using cryo-electron microscopy (cryo-EM). The structure showed
that the antibody binds to domain (D) I, and the DI-DII hinge region
on an envelope protein monomer. Previous studies on HMAb 1F4 had
demonstrated that it only binds to intact virus and not to recombi-
nant envelope (rE) protein. Comparison of cryo-EM structures of virus
E proteins to rE crystal structures showed that the E proteins on the
virus had a conserved DI-DII hinge angle, whereas the hinge angle on
the rE proteins is highly variable. As the DI-DII hinge forms part of
the HMAb 1F4 epitope, we propose that HMAb 1F4 may be very sen-
sitive to the conformation of this region. We also determined the
mechanisms of neutralization of HMAb 1F4 in different cell lines. In
Vero cells, the antibody prevents virus infection at a post-attachment
step, whereas in DC-SIGN-expressing U937 cells, the HMAb can also
prevent virus attachment. Using the cryoEM structure of 1F4 com-
plexed with DENV, we discuss how the antibody could neutralize
these steps of the virus infection.
Impact
We have identified and characterized an antibody that could poten-
tially be used as a DENV1 therapeutic. The results also contribute sig-
nificantly to vaccine design. Firstly, by comparing the HMAb 1F4-
DENV1 structure to another potent HMAb 14c10-DENV1 structure, we
observed an overlap at the DI-DII hinge, suggesting that this region is
likely to be one of the principal determinants in eliciting type-specific
neutralizing antibodies in humans. The inclusion of this region is thus
important for the development of an effective vaccine. In addition,
binding of HMAb 1F4 to E protein monomer is likely to be very sensi-
tive to the hinge conformation. This conformation is held in proper
configuration on the virus by the interactions between E ectodomains
and also the E ectodomains with the E and M stem region. This has
important implications for the development of an effective rE protein-
based vaccine.
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